Features | Partner Sites | Information | LinkXpress
Sign In
JIB
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING

Cannabinoid Receptor Stimulator Reverses Symptoms of Alzheimer's Disease in Animal Model

By BiotechDaily International staff writers
Posted on 12 Sep 2012
A candidate drug that stimulates the activity of cannabinoid type 2 (CB2) receptors in the brain have been shown to reverse the symptoms of Alzheimer's disease in a rodent model.

The drug, 1-((3-benzyl-3-methyl-2,3-dihydro-1-benzofuran-6-yl) carbonyl) piperidine (MDA7), lacks psychoactivity. In a paper published in the July 16, 2012, online edition of the journal Neurobiology of Aging investigators at the Cleveland Clinic (OH, USA) presented results obtained by treating a rat model of Alzheimer's disease with MDA7. Alzheimer's disease was induced in the animals by bilateral microinjection of amyloid-beta (A-beta) 1–40 fibrils into the hippocampal CA1 area of the rats' brains. The animals developed symptoms of a neuroinflammatory process, synaptic dysfunction, and cognitive impairment.

A group of the Alzheimer's rats was treated with intraperitoneal injections of MDA7 daily for 14 days. These animals showed decreased production of inflammatory cytokines and signaling molecules as well as restored cognition, memory, and synaptic plasticity.

"Cleveland Clinic dedicated two years of research into the examination of this compound and our findings show it could represent a novel therapeutic target in the treatment of Alzheimer's disease," said senior author Dr. Mohamed Naguib, professor of anesthesiology at the Cleveland Clinic. "Development of this compound as a potential drug for Alzheimer's would take many more years, but this is a promising finding worthy of further investigation."

Related Links:
Cleveland Clinic




comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Alternative splicing produces two protein isoforms (Photo courtesy of Wikimedia Commons).

Key Regulator of Cancer-Inducing Alternative Splicing Identified

Cancer researchers have identified the splicing factor RBM4 (RNA-binding protein 4) as a key determinant in processes that prevent tumor development and spread. RBM4 is known to be crucial to gene splicing... Read more

Therapeutics

view channel
Image: Hair follicle (blue) being attacked by T cells (green) (Photo courtesy of Christiano Lab/Columbia University Medical Center).

Hair Restoration Method Clones Patients’ Cells to Grow New Hair Follicles

Researchers have developed of a new hair restoration approach that uses a patient’s cells to grow new hair follicles. In addition, the [US] Food and Drugs Administration (FDA) recently approved a new drug... Read more

Lab Technologies

view channel
Image: Leica Microsystems launches the inverted research microscope platform Leica DMi8 (Photo courtesy of Leica Microsystems).

New Inverted Microscope Designed to Readily Adapt to Changing Research Demands

A new inverted microscope for biotech and other life science laboratories was designed to readily accommodate modifications and upgrades to allow it to keep current with changing research demands and interests.... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.